EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Life Healthcare (0928) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Life Healthcare HK$1.20, price HK$1.41, upside -14.6%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK · ISIN KYG5924H1231

LH Thin data Sep 24, 2026

Life Healthcare

0928 · HK

Weak valuationQuality is weak on top of the rich price.

!Fair value HK$1.20 · Overvalued (−14.6%)
!Quality 29/100
!Weak Growth (revenue 5y −8.6 %/yr)
!Loss-making · -49.6% net margin (TTM)
!Moderate debt · negative free cash flow
!Mixed vs. peers (5/10)
!Narrow moat 17/100
!Evidence only low, so the estimate is less certain
Watch Life Healthcare for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$1.96 HK$0.2600 Fair Value HK$1.20 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$0.2600 – HK$1.96 · fair‑value band HK$0.8000 – HK$1.50 · the HK$1.41 price screens above the HK$1.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Life Healthcare in your weekly email

Every Wednesday you see whether Life Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

King International Investment Limited, an investment holding company, provides genetic testing and health data analysis services in the People's Republic of China and Hong Kong. The company operates through two segments, Healthcare Products and Services Business, and Money Lending Business. The company also engages in money lending activities.

Show more

King International Investment Limited, an investment holding company, provides genetic testing and health data analysis services in the People's Republic of China and Hong Kong. The company operates through two segments, Healthcare Products and Services Business, and Money Lending Business. The company also engages in money lending activities. In addition, it provides corporate administrative and healthcare services. The company was formerly known as Life Healthcare Group Limited and changed its name to King International Investment Limited in December 2023. King International Investment Limited was incorporated in 2001 and is based in Central, Hong Kong.

Stock analysis

Life Healthcare (0928) currently trades at HK$1.41, while our model-based Fair Value estimate is HK$1.20, 14.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$0.8000 (bear) to HK$1.50 (bull), the price of HK$1.41 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Life Healthcare reported revenue of HK$40.8M in FY2025 versus HK$102M in FY2021, a compound −20.5%/yr. Reported net income was −HK$47.5M in FY2025.

Key figures

Market cap HK$126M (≈ $16.0M) · P/S ratio 1.62 · EPS (TTM) HK$−0.0200 · Net margin −116% · Return on equity −15.4% · Return on assets (EBIT) −4.3% · Operating margin 12.8% · Revenue (TTM) HK$77.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 142% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −15%, 0928 screens richer than that median.

Fair Value models

Bear HK$0.8000 Fair Value HK$1.20 Bull HK$1.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 54
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 54

Open the full fair value analysis →

Notify me when 0928 reaches fair value

Put 0928 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 29 · Market factors (momentum, volatility) 66

Profitability 2
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 32
Earnings quality: real cash, not paper profit
Fin. Strength 43
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 75
Price trend over the last 3–12 months (market factor)
52W Momentum 72
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−82.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Start year 2020 (pandemic). Over 10 years: +17.1% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−19.7% (2020) → −32.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

0928 screens overvalued: fair value 15% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Life Healthcare with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside +92.7% · Top 25%
Profitability
Return on assets −0.4% · Below median
Net margin (TTM) −49.6% · Bottom 25%
Operating margin (TTM) 12.8% · Above median
Growth and dividend
Revenue growth 98.8% · Top 25%
Balance sheet
Debt / equity 0.54× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.07× · Cheapest 25%
P/S (TTM) 0.21× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 11
HEALTH (low debt)73 · sector 93
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Life Healthcare · Fair Value
HK$1.20 −15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Life Healthcare Fair Value". https://www.fairvalue-calculator.com/stock/0928

Frequently asked questions

Is Life Healthcare (0928) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$1.20 versus a price of HK$1.41, about −15% upside (overvalued).
What is the fair value of 0928?
Our model-based fair value for Life Healthcare is HK$1.20 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$1.41.
What is the quality score of 0928?
Life Healthcare has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Life Healthcare (0928)?
Our model-based price target is the fair value of HK$1.20 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$0.8000, optimistic scenario HK$1.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Life Healthcare stock forecast for 2026?
Our models put fair value at HK$1.20, about −15% upside versus a price of HK$1.41 (overvalued). Cautious scenario HK$0.8000, optimistic scenario HK$1.50. The calculation is refreshed regularly with new filings.
What is the revenue of Life Healthcare (0928)?
Life Healthcare reported trailing-twelve-month revenue of about HK$77.5M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Life Healthcare (0928)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Life Healthcare it is HK$1.20 per share (as of Sep 24, 2026), against a price of HK$1.41. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Life Healthcare stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0928 trades above its calculated fair value: price HK$1.41, fair value HK$1.20, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0928?
No. The price is what the market pays today (HK$1.41); the fair value is what the company's own numbers justify (HK$1.20). For Life Healthcare the two are HK$0.2050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Life Healthcare worth?
The market values Life Healthcare at about HK$126M (market capitalisation, as of Sep 24, 2026). Per share that is HK$1.41; our models calculate a fair value of HK$1.20 per share.
What do the bullish and bearish scenarios say about 0928?
Our models span a range for Life Healthcare: cautious scenario HK$0.8000, base HK$1.20, optimistic HK$1.50 per share (as of Sep 24, 2026, price HK$1.41). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Life Healthcare (0928)?
Balance-sheet figures for Life Healthcare (as of Sep 24, 2026): return on equity −15.4%, debt of 0.54 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 0928 from its 52-week high?
Life Healthcare trades at HK$1.41, about 6% below its 52-week high of HK$1.49 and 142% above the low of HK$0.5800 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.20 is for.
Which stocks are comparable to Life Healthcare?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Life Healthcare stock attractive at the current price?
The data as of Sep 24, 2026: price HK$1.41, calculated fair value HK$1.20 (−15%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0928 calculated?
We run Life Healthcare through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.20, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Life Healthcare itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Life Healthcare (0928)?
The closing price on Oct 2, 2026 was HK$1.41. Our model-based fair value is HK$1.20, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Life Healthcare right now?
A fairly wide model range (HK$0.8000 to HK$1.50) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Life Healthcare

How large is the market capitalisation of Life Healthcare (0928)?
The market capitalisation of Life Healthcare is HK$126M (≈ $16.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Life Healthcare (0928)?
The price-to-sales ratio of Life Healthcare is 1.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Life Healthcare (0928)?
Earnings per share at Life Healthcare are HK$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Life Healthcare (0928)?
The net margin of Life Healthcare is −116% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Life Healthcare (0928)?
The return on equity (ROE) of Life Healthcare is −15.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Life Healthcare (0928)?
On an EBIT basis the return on assets of Life Healthcare is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Life Healthcare (0928)?
The operating margin of Life Healthcare is 12.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Life Healthcare (0928)?
Revenue at Life Healthcare is growing +98.8% versus a year earlier (3y avg −24.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Life Healthcare (0928) generate?
The free cash flow of Life Healthcare is −HK$322K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Life Healthcare (0928) carry?
The net debt of Life Healthcare is HK$2.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Life Healthcare in the live analysis

One click puts Life Healthcare on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.